(NASDAQ: ZNTL) Zentalis Pharmaceuticals's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 11.45%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 35.74%.
Zentalis Pharmaceuticals's earnings in 2026 is -$137,060,000.On average, 11 Wall Street analysts forecast ZNTL's earnings for 2026 to be -$137,286,981, with the lowest ZNTL earnings forecast at -$163,354,130, and the highest ZNTL earnings forecast at -$94,586,510. On average, 10 Wall Street analysts forecast ZNTL's earnings for 2027 to be -$117,929,907, with the lowest ZNTL earnings forecast at -$164,744,378, and the highest ZNTL earnings forecast at -$60,326,829.
In 2028, ZNTL is forecast to generate -$105,871,634 in earnings, with the lowest earnings forecast at -$148,061,403 and the highest earnings forecast at -$36,494,008.